Compare KAI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KAI | MLYS |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | KAI | MLYS |
|---|---|---|
| Price | $321.12 | $32.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $340.00 | $47.33 |
| AVG Volume (30 Days) | 126.2K | ★ 1.2M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $1,024,074,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.56 | N/A |
| P/E Ratio | $37.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $244.87 | $8.24 |
| 52 Week High | $409.73 | $47.65 |
| Indicator | KAI | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 41.60 |
| Support Level | $310.20 | $30.96 |
| Resistance Level | $334.50 | $34.65 |
| Average True Range (ATR) | 11.40 | 1.86 |
| MACD | 1.30 | 0.05 |
| Stochastic Oscillator | 76.70 | 26.11 |
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.